Trial Profile
An Open-label Trial to Assess the Efficacy and Safety of Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 28 Nov 2018
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Immune-mediated uveitis; Juvenile rheumatoid arthritis
- Focus Therapeutic Use
- 04 Apr 2016 Status changed from recruiting to discontinued due to insufficient enrolment as reported by ClinicalTrials.gov.
- 21 Apr 2015 New trial record